
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The need to provide both operator and product protection while developing more efficient containment strategies has initiated a wave of innovative solutions in barrier/isolation equipment design and implementation.
over 22 years ago
Pharmaceutical Pricing and Healthcare Accessover 22 years ago
The Effect of Buffers on Protein Conformational Stabilityover 22 years ago
Packaging Helps Protect Temperature-Sensitive Productsover 22 years ago
Resealed Erythrocytes: A Reviewover 22 years ago
Connecting Clinical Trial Management to Pharmaceutical Manufacturingover 22 years ago
March 2003over 22 years ago
Stakes Getting Higher for Contractors




